Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer.
about
Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancerPhase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma.Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma.Prioritization schema for immunotherapy clinical trials in glioblastoma.nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors.The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future.Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer.T cell exhaustion: from pathophysiological basics to tumor immunotherapy.Immune-related neurological toxicities among solid tumor patients treated with immune checkpoint inhibitors: a systematic review.Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review.Phase II study of Amrubicin monotherapy in elderly or poor-risk patients with extensive disease of small cell lung cancer.Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes.Immunotherapy in the Asiatic population: any differences from Caucasian population?Clinical significance of programmed death 1 ligand-1 (CD274/PD-L1) and intra-tumoral CD8+ T-cell infiltration in stage II-III colorectal cancer
P2860
Q26740288-6AD271E8-40BA-41CF-97BD-C59AC16605D9Q36181269-3236C112-31A3-4A98-B19D-8060B54B6742Q36181274-9B26A801-0A7E-4F05-BEF9-EED8FDBD1F00Q37078999-3EDC2ECF-6B1C-4E3C-B6F2-B2DC1EB2A29DQ37536367-271A7460-6E0C-4D7C-B4E8-AC0104FD9C38Q38401891-BF09CE39-2524-438D-9963-7267D9E27E40Q38687631-029BE801-378A-4CEE-ABE8-0EFD1146A973Q38899873-D857563B-795D-4007-A45F-C3CC8DA05D8AQ38916160-1F983D71-9D81-43D4-9BF1-65FF1D98795DQ39078341-28557B40-D341-4FC2-80A7-C0732FEB6DF4Q39332694-58A7B3C0-7F23-4856-B283-E1E7F1F00511Q46694815-A9EA8B9C-C97A-4E42-81CE-9970D14202ADQ47857422-C0FEB8EE-9E75-41D8-837B-B4F701CE65BCQ48535444-1316FAAC-33A4-42FE-AD48-50C46A0E0028Q50345931-43B819EC-C22B-4B4B-A59B-D6F81391CF5AQ55312983-3F3B74E5-8200-4B73-86B4-5B2EEB913F20Q57799745-161F3379-A783-447F-A443-7413C4F6CDFD
P2860
Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Phase I study of ipilimumab in ...... th non-small-cell lung cancer.
@ast
Phase I study of ipilimumab in ...... th non-small-cell lung cancer.
@en
type
label
Phase I study of ipilimumab in ...... th non-small-cell lung cancer.
@ast
Phase I study of ipilimumab in ...... th non-small-cell lung cancer.
@en
prefLabel
Phase I study of ipilimumab in ...... th non-small-cell lung cancer.
@ast
Phase I study of ipilimumab in ...... th non-small-cell lung cancer.
@en
P2093
P2860
P1476
Phase I study of ipilimumab in ...... ith non-small-cell lung cancer
@en
P2093
Hidehito Horinouchi
Hidenori Mizugaki
Hiroshi Nokihara
Hiroshi Wakui
Ikuo Sekine
Kaoru Kubota
Noboru Yamamoto
Satoru Kitazono
Shigehiro Yagishita
Shintaro Kanda
P2860
P2888
P304
P356
10.1007/S10637-015-0243-5
P577
2015-05-01T00:00:00Z